World OTC Pharmaceutical Market Forecast 2016-2026

11 September 2016
Pharma

A new report by visiongain predicts that the Over-the-Counter Pharmaceuticals market will reach $127.0bn in 2016. This forecast and others appear in World OTC Pharmaceutical Market Forecast 2016-2026: Recent M&A Activity and Prospects for Rx-to-OTC Switching in Cough, Cold and Allergy, Analgesics, Gastrointestinal Medicines, and Other Leading Segments published in March 2016. Visiongain is a business information provider based in London, UK.

World OTC Pharmaceutical Market Forecast 2016-2026, report examines the current and future trends in the Over-the-Counter Pharmaceuticals market with particular focus on recent pivotal developments in the sector involving launches of new first-in-class OTC switch medicines and the many major acquisitions that have taken place between large pharmaceutical companies in the last few years and those in the pipeline for 2016. These developments have changed the landscape of consumer healthcare.

Over-the-Counter medicines are pharmaceuticals that are available for sale to the general public without requiring a prescription. The term “over-the-counter” generally refers to pharmaceuticals, which can be bought across any counter (i.e. not exclusively through a registered pharmacy). However, this is significant variation in this across different regions.

OTC medicines are used to prevent and treat relatively minor ailments, as populations increase and are aging there is a growing push to be able to licence OTC medicines for use in the treatment of chronic conditions.

With the recent first-in-class OTC switches of the last few years the industry is set for changes in consumer uptake and perception. The major acquisitions that have been undertaken by major pharmaceutical companies which involve their consumer healthcare divisions are set to continue with further transactions in negotiations currently. This re-focusing of the consumer healthcare divisions will result in companies paying greater focus on their new acquisitions and the lucrative consumer health care market and thus invest in it further driving growth in this sector.

In this report, we examine in detail the factors which are driving the OTC pharmaceutical market to grow at a faster rate than the overall pharmaceutical market, the key companies currently operating in the consumer healthcare sector and the impacts of any transactions that have occurred or are in the pipeline. We also examine key national markets and discuss trends and variations within these markets alongside an analysis of international OTC brands and their strengths. The OTC categories examined in this report are: cough, cold and allergy, analgesics, dermatologicals, gastrointestinals, eye care, and smoking cessation aids. National Markets focused on are the US, China, Japan, countries which make up the EU5, Brazil, Russia, India and Mexico.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading drugs and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Also included is analysis of the current leading players in the Over-the-Counter Pharmaceutical market: historical financial performance is analysed, along with a breakdown of each company’s leading products, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Visiongain’s report provides revenue and growth forecasts for 9 of the leading companies in the over-the-counter medicines market and analysis of their key brands. For each company, a ten year forecast is given alongside in depth review and analysis.

Dipika Sachdev, a pharmaceutical and medical devices industry analyst in visiongain, said: “We predict the rate of OTC pharmaceutical market growth will be higher over the forecast period as compared to the whole pharmaceutical market. With the healthy growth of traditional OTC categories such as cough, cold and allergy and gastrointestinal medication will be revitalised building on the success of recent first in class OTC switches in these categories. We believe this industry is being reinvigorated by the shifting attitudes that healthcare regulators are having towards non-prescription drugs, this compounded with the healthy well-informed customer using digital technology to prevent illness and improve long-term health, if managed appropriately both these factors will fuel significant growth in this sector. New OTC categories that may reach major markets during the forecast period include antihypertensive drugs and other drugs used in the treatment of long –term chronic symptomatic conditions. It is uncertain whether more chronic diseases can be self-medicated with the necessary precaution barriers; however it is a real possibility as healthcare systems attempt to control spiraling costs.”
Visiongain’s report provides revenue forecasts to 2026 for the Over-the-Counter pharmaceuticals market and its leading drugs, submarkets and international markets. The report discusses selected leading companies which hold significant shares of the market. These companies include GSK Consumer Health, Bayer, Johnson and Johnson, Perrigo, Pfizer, Procter and Gamble, Reckitt Benckiser, Sanofi, and Boehringer Ingelheim. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

World OTC Pharmaceutical Market Forecast 2016-2026: Recent M&A Activity and Prospects for Rx-to-OTC Switching in Cough, Cold and Allergy, Analgesics, Gastrointestinal Medicines, and Other Leading Segments adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever